ArticleFrontiers in medicine2023

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib.

Sara Völkel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.